Bayer Healthcare has admitted to 12 breaches of the ABPI Code after one of its staff developed and distributed drug information without the company’s knowledge. In a highly embarrassing move, Bayer revealed that three documents relating to Bayer’s oral anticogulant Xarelto (rivaroxaban) were not submitted for review and certification (breaching clause 14.1). The first the company knew of the imbroglio was when a service improvement manager for an NHS heart and stroke network wrote to Bayer with her concerns about a proposal for joint working she had received.
